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Abstract: Psychosis of Alzheimer’s disease (AD) is characterized by delusions or hallucinations 
and may be associated with agitation, negative symptoms or depression. There are no psycho-
tropic medications that are approved by the US FDA for the treatment of psychosis of AD. 
However, atypical antipsychotics have been widely used and recommended by geriatric experts 
in the management of psychosis of AD in view of the modest efﬁ  cacy and relative safety until 
FDA warnings were issued in 2005 and meta-analytic studies showed no signiﬁ  cant difference 
to placebo. The FDA warnings on the cardiac, metabolic, cerebrovascular, and mortality risks 
have caused serious concerns for the use of atypical antipsychotic agents in elderly patients 
with dementia. Only a few studies have evaluated prospectively the effects of aripiprazole in 
psychosis associated with AD. These studies show improvement in the symptoms of psychosis 
associated with AD with aripiprazole. The safety and tolerability proﬁ  le of aripiprazole 
suggests a low potential for negative impact on dementia and overall patient health. Further 
studies comparing the efﬁ  cacy and tolerability of aripiprazole vs other atypical antipsychotics 
in dementia are needed.
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Introduction
Alzheimer’s disease (AD) affects 5%–15% of the population over 65 years, and about 
20% of individuals over 80 years. AD is characterized by a gradual onset of multiple 
cognitive deﬁ  cits and is associated with continuing cognitive decline. There is a high 
prevalence of psychotic symptoms (Paulsen et al 2000) and behavioral disturbances 
in AD (Devanand et al 1992; Eustace et al 2002). A review of studies that assessed 
the prevalence of psychosis associated with AD showed a median prevalence rate of 
41.1% (range, 12.2%–74.1%) (Ropacki and Jeste 2005); however, the patients fol-
lowed up in the outpatient clinics showed lower rates (Bassiony et al 2000). Psychotic 
symptoms have been linked to increased cognitive and functional decline (Chui et al 
1994; Lopez et al 1999) leading to caregiver distress (Everitt et al 1991; Hopkins and 
Libon 2005) and an increased likelihood of institutionalization (Lopez et al 1999) 
in patients with AD. Jeste and Finkel (2000) have deﬁ  ned the diagnostic criteria for 
psychosis of AD (Table 1).
Among the psychotropic medications, antipsychotics are the most studied treat-
ment for psychosis, aggression, and agitation in elderly patients with dementia (Doody 
et al 2001; Kindermann et al 2002). These studies have shown the efﬁ  cacy of atypi-
cal antipsychotics in treating some of the behavioral symptoms that are associated 
with AD (Katz et al 1999; Street et al 2000; Tariot et al 2002; Brodaty et al 2003; 
De Deyn et al 1999, 2004; Zhong et al 2004). Even though there is no psychotropic 
medication that is approved by the US Food and Drug Administration (FDA) for the 
treatment of psychosis of AD, a number of expert consensus statements recommend 
the use of atypical antipsychotic agents as a ﬁ  rst-line pharmacologic approach to Clinical Interventions in Aging 2008:3(3) 492
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treatment (Alexopoulos et al 2004; AGS/AAGP). Despite 
these ﬁ  ndings, only a few studies have prospectively evalu-
ated the antipsychotic effects of this class of compounds 
in patients with AD using the criteria deﬁ  ned by Jeste and 
Finkel (2000). In contrast, most published studies with 
atypical agents have also included patients with vascular and 
mixed dementias, and those with behavioral disturbances, 
such as agitation.
Safety and tolerability of a medication is of great concern 
while treating the elderly due to their increased sensitivity 
to adverse events (AEs), the increased likelihood of co-
morbid health problems (eg, cardiovascular disease), and 
the potential for some side effects to worsen the progression 
of dementia (Kindermann et al 2002). Studies have shown 
that risperidone, olanzapine, and quetiapine can reduce 
psychotic symptoms and behavioral disturbances in patients 
with dementia (Katz et al 1999; Deﬁ  lippi and Crismon 2000; 
Street et al 2000; Madhusoodanan et al 2001; Tariot et al 
2002; Brodaty et al 2003; De Deyn et al 1999, 2004; Zhong 
et al 2004. However, the side-effect proﬁ  les of individual 
atypical antipsychotics, especially the metabolic effects 
may adversely inﬂ  uence their overall effectiveness and 
acceptability (Jeste et al 1999; Masand 2000). Movement 
disorders, sedation, and orthostasis are associated with an 
increased risk of falls and subsequent fractures. Anticho-
linergic side effects may lead to delirium in the elderly and 
require additional treatment. Analyses of safety data from 
several studies have raised concerns about an increased risk 
of cerebrovascular adverse events (CVAEs), such as stroke, 
with the use of some atypical antipsychotics compared with 
placebo in elderly patients with dementia (Wooltorton 2002, 
2004). This has led FDA to issue warnings on the use of 
atypical antipsychotics in the treatment of behavioral and 
psychological symptoms in elderly patients with dementia, 
particularly those with a history of cerebrovascular disease 
(US FDA 2003; Health Canada; MHRA). More recently, 
the FDA issued a separate warning regarding an increased 
mortality risk in elderly patients with dementia who were 
treated with atypical antipsychotics (US FDA 2005). We 
have dealt with these issues in detail in our recent review 
article (Madhusoodanan et al 2007).
Aripiprazole is a novel atypical antipsychotic that has 
shown rapid and sustained efﬁ  cacy and tolerability in short-
term and long-term controlled clinical trials and retrospective 
studies in patients with schizophrenia, schizoaffective disor-
der and bipolar disorder (Liebermann 2004; Madhusoodanan 
et al 2004; Sajatovic et al 2008). Recently FDA approved the 
use of aripiprazole as an adjunctive to antidepressants for the 
treatment of major depressive disorder in adults (Prescrib-
ing information 2007). Aripiprazole is a partial D2-receptor 
agonist (Burris et al 2002), 5-HT2A receptor antagonist 
(Byars et al 2002), and a partial agonist at 5-HT1A recep-
tors (Jordan et al 2002). In addition, aripiprazole has been 
shown to exhibit moderate afﬁ  nity for the alpha1, alpha2 and 
Table 1 Diagnostic Criteria for psychosis of Alzheimer’s disease (PAD) (after Jeste and Finkel 2000)
Characteristic symptoms
Presence of 1 of the following:
Visual or auditory hallucinations
Delusions
Primary diagnosis
All criteria for dementia of Alzheimer’s type are met.
Chronology of onset of psychosis symptoms versus onset of dementia symptoms
There is evidence from the history that the characteristic symptoms have not been present continuously before the onset of dementia symptoms.
Duration and severity
Characteristic symptoms have been present, at least intermittently, for 1 month. Symptoms are severe enough to cause some disruption in the patient’s 
and/or other’s functioning.
Exclusion of schizophrenia and related psychotic disorders
Criteria for schizophrenia, schizoaffective disorder, delusional disorder, or mood disorder with psychotic features have never been met.
Relationship to delirium
The disturbance does not occur exclusively during course of a delirium.
Exclusion of other causes of psychotic symptoms
The disturbance is not better accounted for by another general medical condition or direct physiological effects of a substance (eg, a drug of abuse or 
medication).
Associated features (specify)
With agitation-when there is evidence from history or examination of prominent agitation with or without physical or verbal aggression.
With negative symptoms – when prominent negative symptoms, such as apathy, affective ﬂ  attening, avolition, or motor retardation, are present.
With depression – when prominent depressive symptoms, such as depressed mood, insomnia or hypersomnia, feelings of worthlessness or excessive 
or inappropriate guilt, or recurrent thoughts of death, are present.Clinical Interventions in Aging 2008:3(3) 493
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histamine H1 receptors and negligible afﬁ  nity for muscarinic 
M1 receptors (DeLeon et al 2004; Prescribing information 
2007).
Three 10-week, placebo-controlled, randomized, double-
blind clinical studies have evaluated the efﬁ  cacy and toler-
ability of aripiprazole for the treatment of psychosis related 
to AD (Table 2a) (Streim et al 2004; De Deyn et al 2005; 
Mintzer et al 2007). Of these, the studies conducted by De 
Deyn et al and Streim et al examined ﬂ  exible dosing of 
aripiprazole (2–15 mg/d), and Mintzer et al studied ﬁ  xed 
doses of aripiprazole (2 mg/d, 5 mg/d, 10 mg/d). Patients 
in the Streim et al and Mintzer et al studies were either full 
time nursing home or assisted living facility residents, while 
patients in the De Deyn et al study were living in assisted 
living facilities or adult communities, or with a caregiver. The 
inclusion criteria were delusions/hallucinations lasting for 1 
month or longer, Mini Mental State Exam (MMSE; Fostein 
et al 1975) score of 6–24, and score of more than 6 on delu-
sions or hallucinations items of Neuropsychiatric Inventory 
(NPI; Cummings et al 1994) scale at baseline.
In the De Deyn et al (2005) study, 208 outpatients (mean 
age 81.5 years, range 55–95) with AD-associated psychosis 
and mean MMSE score of 14.35 (aripiprazole) and 14.13 
(placebo), were randomized to aripiprazole (n = 106) or 
placebo (n = 102). The initial aripiprazole dose of 2 mg/d was 
titrated upwards (5, 10, or 15 mg/d) usually every 2 weeks 
according to efﬁ  cacy and tolerability. Overall, 172 patients 
(83%) completed the study. Mean aripiprazole dose at end 
point was 10.0 mg/d. Patients in this study were noninstitu-
tionalized, in contrast to most studies with other atypicals 
published to date, which included institutionalized patients 
(Katz et al 1999; Street et al 2000; Tariot et al 2002; Brodaty 
et al 2003; De Deyn et al 1999, 2004; Zhong et al 2004). In 
this study, the degree of cognitive impairment (mean MMSE, 
14.35 for aripiprazole, 14.13 for placebo) was less compared 
with most of the studies with other atypicals (mean MMSE, 
6.1–9.3).
In the Streim et al (2004) study, 256 inpatients (mean age 
83 years, range 59–96) with AD-associated psychosis and 
mean MMSE score of 12.9 were randomized to aripiprazole 
(n = 131) or placebo (n = 125). The suggested titration for 
this study was: week 1: 2 mg/d; week 2–3: 5mg/d; week 
4–5: 10 mg/d; week 6–10: 15 mg/d. Mean aripiprazole dose 
at end point was 8.6 mg/d.
Table 2a Methodology – placebo-controlled studies of aripiprazole in patients with AD-related psychosis (pers comm Jan 8 2008, 
Bristol-Myers Squibb and Otsuka Pharmaceutical Co, Ltd, Data on ﬁ  le)
Reference Patient population Study design Study medication
De Dedyn et al 2005 208 outpatients
Mean age (in years) 81.5, 
range 55–95
Mean MMSE score = 14.35 
(aripiprazole).
14.13 (placebo)
delusions/
hallucinations  1 month
NPI delusions/
hallucinations score 6
10 week, randomized double-blind, 
multi-center placebo-controlled, 
ﬂ  exible dose study
Aripiprazole 2–15 mg/d 
(n = 106)
Titrated Q 2 weeks as needed
Mean end point dose = 10 mg/d
Placebo (n = 102)
Streim et al 2004 256 inpatients
Mean age (in years) 83; 
range 59–96
Mean MMSE score = 12.9
delusions/
hallucinations  1 month
NPI delusions/
hallucinations score 6
10 week, randomized double-blind, 
multi-center placebo-controlled, 
ﬂ  exible dose study
Aripiprazole 2–15 mg/d
(n = 131)
Week 1 to weeks 6–10 from 
2 mg/d to 15 mg/d
Mean end point dose = 8.6 mg/d
Placebo (n = 125)
Mintzer et al 2007  487 inpatients
Mean age, years 82.2, 
(range) 56.0–96.0
Mean MMSE score = 12.4
delusions/hallucinations 
 1 month
NPI delusions/ 
hallucinations score 6
10 week, randomized double-blind, 
multi-center placebo-controlled, 
ﬁ  xed dose study
Aripiprazole 2 mg/d (n = 118)
Aripiprazole 5 mg/d (n = 122)
Aripiprazole 5 mg/d × 7d, then 
10 mg/d (n = 126)
Placebo (n = 121)
by week 6, patient 
with CGI-I 4 were allowed 
open-label treatment with 
aripiprazole through week 10
Abbreviations: CGI-I, Clinical Global Impression of Improvement; MMSE, Mini Mental State Exam; NPI, Neuropsychiatric Inventory.Clinical Interventions in Aging 2008:3(3) 494
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In the Mintzer et al (2007) study, 487 inpatients (mean 
age 82.5 years, range 56–97) with AD-associated psychosis 
and mean MMSE score of 12.4 were randomized to ﬁ  xed 
doses of aripiprazole, 2 mg/d (n = 118), 5 mg/d (n = 122), 
10 mg/d (n = 126) (patients were started on 5 mg/d for 7 days 
and the dose was then increased to 10 mg/d), or placebo 
(n =  121). By week 6, patients with Clinical Global Impres-
sion of Improvement (CGI-I; Guy 1976) score of 4 were 
allowed open-label treatment with aripiprazole through week 
10. In total, 284 patients completed 10 weeks of double-blind 
therapy.
Results
Efﬁ  cacy (Table 2b)
Primary outcome measures
In the De Deyn et al (2005) study, the caregiver-assessed 
NPI Psychosis subscale (Cummings et al 1994) score 
showed improvements in both groups (aripiprazole −6.55, 
placebo −5.52; p = 0.17 at end point), but the difference between 
aripiprazole and placebo was not statistically signiﬁ  cant.
In the Streim et al (2004) study, there was no statistically 
signiﬁ  cant difference between aripiprazole and placebo on 
the NPI Psychosis subscale score at week 10. There were 
decreases in Clinical Global Impression-Severity of Illness 
(CGI-S; Guy 1976) scores in both aripiprazole and placebo 
groups, but the difference in the mean change in CGI-S in 
aripiprazole vs placebo was signiﬁ  cant (p  0.05) only at 
week 8.
In the Mintzer et al (2007) study, there was a statistically 
signiﬁ  cant difference between aripiprazole and placebo 
(aripiprazole 10 mg/d, −6.87. placebo, −5.13. p 0.013) on 
the Neuropsychiatric Inventory-Nursing Home (NPI-NH) 
Psychosis subscale (Guy 1976; Cummings et al 1994; Wood 
et al 2000) score at week 10. Mean change in NPI-NH Psy-
chosis subscale score was also signiﬁ  cant for the aripiprazole 
5 mg group vs placebo at week 8 (p  0.05). There was a 
statistically signiﬁ  cant difference (p  0.05) in the response 
to treatment as deﬁ  ned by 50% reduction in the NPI-NH 
Psychosis subscale score at week 10 for aripiprazole (65%) 
vs placebo (50%).
Secondary outcome measures
In the De Deyn et al (2005) study, aripiprazole-treated 
patients showed signiﬁ  cantly greater improvements from 
baseline in physician assessed Brief Psychiatric Rating Scale 
(BPRS) (Overall and Gorham 1962) Psychosis and BPRS 
Core subscale scores at end point compared with placebo. 
There were no statistically signiﬁ  cant differences between 
aripiprazole and placebo in the mean change in BPRS total 
score (aripiprazole −8.53, placebo −6.58; p value not signiﬁ  -
cant), NPI total (aripiprazole −9.75, placebo −11.20; p value 
not signiﬁ  cant), CGI-S (aripiprazole −0.69, placebo −0.54; 
p value not signiﬁ  cant ), CGI-I (aripiprazole 3.17, placebo, 
3.07; p value not signiﬁ  cant). Patients in both the aripipra-
zole and placebo groups showed little change in cognitive 
function over the course of the study, with minimal mean 
changes (1 point) in MMSE score observed from baseline 
to end point (aripiprazole −0.81, placebo −0.53; p 0.001). 
The investigators explained the small improvement in MMSE 
scores seen in the placebo group as a possible response to the 
increased attention patients received during the study. The 
minimal changes observed in both groups and high mean 
baseline scores, coupled with the wide variation in baseline 
MMSE scores (from 2 to 23), suggested that these are of 
little clinical signiﬁ  cance. Aripiprazole has negligible afﬁ  nity 
for muscarinic M1 receptors, and hence has a low potential 
for cognitive impairment, and has shown improvements in 
cognitive function in a study in patients with schizophrenia 
or schizoaffective disorder (Cornblatt et al 2002).
In the Streim et al (2004) study, there was a statistically 
signiﬁ  cant difference (p = 0.006) in the response to treatment 
as deﬁ  ned by 50% reduction in the NPI total score at week 
10 for aripiprazole (46%) and placebo (28%). There were 
statistically signiﬁ  cant improvements in the NPI-NH total 
scores (aripiprazole −16.4, placebo −10.0; p 0.009), BPRS 
total score (aripiprazole, −7.7 placebo, −5.1; p 0.031) and 
Cornell Depression in Dementia Scale (CDDS; Alexopoulos 
et al 1988) total score (aripiprazole −0.13, placebo −1.98; 
p 0.006) at week 10. There were statistically signiﬁ  cant 
(p  0.05) improvements with aripiprazole vs placebo group 
in Cohen-Mansﬁ  eld Agitation Inventory (CMAI; Cohen-
Mansﬁ  eld and Billig 1986; Cohen-Mansﬁ  eld 1995; Miller 
et al 1995; Weiner et al 2002) and CGI-I scores.
In the Mintzer et al (2007) study, there was a statisti-
cally signiﬁ  cant improvement at week 10 with aripiprazole 
10 mg/d vs placebo group in BPRS total score (aripip-
razole −7.12, placebo −4.17; p 0.03) and in the CGI-S 
(aripiprazole −0.72, placebo, −0.46; p 0.031). There was a 
signiﬁ  cant reduction in the CMAI scores with aripiprazole 
5 mg/d and 10 mg/d vs placebo at weeks 6 through 10. 
There was a signiﬁ  cant reduction in the BPRS core score 
with aripiprazole 5 mg/d vs placebo at weeks 4, 6, and 8, 
and with 10 mg/d vs placebo at weeks 4 through 10. There 
was a signiﬁ  cant reduction in the NPI-NH total score with 
aripiprazole 5 mg/d vs placebo at weeks 6 and 8. Aripipra-
zole 2 mg/day was not efﬁ  cacious.Clinical Interventions in Aging 2008:3(3) 495
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Kostic et al (2005) analyzed the data from the two 
studies (Streim et al 2004; Mintzer et al 2007) to investigate 
further the effect of aripiprazole on agitation as measured 
by reduction in NPI-Agitation Item, CMAI, and Tension/
Hostility/Uncooperativeness/ Excitement scores of BPRS. 
In the Streim et al (2004) study, NPI agitation/aggression, 
CMAI, and BPRS Tension/Hostility/Uncooperativeness/
Excitement scores were significantly reduced at study 
endpoint (p  =  0.001, p  0.05, p  0.05 respectively). 
In the Mintzer et al (2007) study, aripiprazole 5 mg/d and 
10 mg/d demonstrated signiﬁ  cant reduction (p  0.05) of 
NPI-NH Agitation Item and BPRS Tension/Hostility/Unco-
operativeness/Excitement subscore compared with placebo. 
A signiﬁ  cant decrease from baseline on BPRS Tension/
Hostility/Uncooperativeness/Excitement subscore was also 
observed with aripiprazole 2 mg/d (beginning at week 6) 
at study endpoint (p  0.05). The effect of aripiprazole on 
agitation as measured by BPRS Tension/Hostility/Uncoop-
erativeness/Excitement subscore was seen earlier with higher 
doses (beginning at week 2 with 10 mg/d and beginning at 
week 4 with 5 mg/d) compared with 2 mg/d.
Discontinuation due to lack of efficacy occurred in 
3 patients on aripiprazole and 6 patients on placebo in the 
De Deyn et al (2005) study, and in 1 patient on aripiprazole 
and 3 patients on placebo in the Streim et al study (2004). 
Discontinuation due to lack of response occurred in 13% 
of patients on aripiprazole vs 30% of patients on placebo, 
and time to discontinuation was signiﬁ  cantly longer in the 
aripiprazole group vs the placebo group (p = 0.022) in the 
Streim et al (2004) study. In the Mintzer et al (2007) study, 
discontinuation due to lack of efﬁ  cacy occurred in 3% of 
patients on 2 mg/d of aripiprazole, 2% of patients on 5 mg/d 
of aripiprazole, 2% of patients on 10 mg/d of aripiprazole, 
and 2% of patients on placebo. Discontinuation due to lack 
of response occurred in 21% of patients on 2 mg/d of aripip-
razole, 16% of patients on 5 mg/d of aripiprazole, 13% of 
patients on 10 mg/d of aripiprazole, and 24% of patients on 
placebo. Thus the discontinuation due to lack of response was 
highest in the lowest-dose group and placebo group.
Tolerability (Table 2c)
In the De Deyn et al (2005) study, AEs were generally mild 
to moderate and included (aripiprazole vs placebo): urinary 
tract infection (8% vs 12%), accidental injury (8% vs 5%), 
somnolence (8% vs 1%), and bronchitis (6% vs 3%). Som-
nolence was mild and not associated with falls or accidental 
injury. There were no signiﬁ  cant differences vs placebo in 
the extrapyramidal symptoms (EPS) scores, or clinically 
signiﬁ  cant electrocardiogram (ECG) abnormalities, vital 
signs, or weight.
In the Streim et al (2004) study, AEs that occurred at 
the rate of 10% in the aripiprazole group were accidental 
injury, somnolence, urinary tract infection, ecchymosis, 
asthenia, vomiting, and rash, and in the placebo group were 
accidental injury, urinary act infection, ecchymosis, and rash. 
EPS occurred in 5% of aripiprazole group vs 4% of placebo 
group, somnolence occurred in 14% of aripiprazole group 
vs 4% of placebo group, and accidental injuries occurred in 
21% of aripiprazole group vs 30% of placebo group.
In the Mintzer et al (2007) study, AEs occurring at 
10% incidence in any dosage group of aripiprazole were 
accidental injury, agitation, peripheral edema, extremity 
pain, somnolence, urinary incontinence, asthenia, vomiting, 
and skin ulcer, and in the placebo group, accidental injury, 
anorexia, ecchymosis, and agitation. EPS occurred in 8% of 
aripiprazole 2 mg/d group, 7% in aripiprazole 5 mg/d group, 
7% in aripiprazole 10 mg/d group, and 6% in the placebo 
group. Somnolence occurred in 3% of aripiprazole 2 mg/d 
group, 10% in aripiprazole 5 mg/d group, 7% in aripiprazole 
10 mg/d group, and 3% in the placebo group. Accidental 
injuries occurred in 30% of aripiprazole 2 mg/d group, 24% 
in aripiprazole 5 mg/d group, 20% in aripiprazole 10 mg/d 
group, and 19% in the placebo group.
Analysis of the data on mortality in elderly patients with 
dementia-related psychosis (Breder et al 2005; pers comm 
Jan 8 2008, Bristol-Myers Squibb and Otsuka Pharmaceutical 
Co, Ltd, Data on ﬁ  le) of the three trials (Streim et al 2004; De 
Deyn et al 2005; Minzter et al 2007) for deaths that occurred 
during or within 30 days of discontinuation from the placebo-
controlled phase of the clinical trial showed that incidence 
of deaths was 3.5% in aripiprazole-treated patients and 1.7% 
in placebo-treated patients (p = 0.139). None of the deaths 
were considered to be treatment-related. Deaths were mostly 
associated with cardiovascular or infectious conditions.
In these three trials (Streim et al 2004; De Deyn et al 
2005; Minzter et al 2007), there was increased incidence 
of CVAEs (eg, stroke, transient ischemic attack), including 
fatalities, in aripiprazole-treated patients. In the ﬁ  xed-dose 
study of Mintzer et al (2007) there was a statistically sig-
niﬁ  cant dose-response relationship for CVAEs in patients 
treated with aripiprazole.
In an analysis (pers comm Jan 8 2008, Bristol-Myers 
Squibb and Otsuka Pharmaceutical Co, Ltd, Data on ﬁ  le) 
of the three 10-week, placebo-controlled studies of aripip-
razole in elderly patients with psychosis associated with 
AD (n = 938, mean age 82.4 years, range 56–99 years), the Clinical Interventions in Aging 2008:3(3) 497
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treatment-emergent AEs that were reported at an incidence 
of 3% and at least twice that for placebo were lethargy 
(placebo 2%, aripiprazole 5%), somnolence (including 
sedation) (placebo 3%, aripiprazole 8%), and incontinence 
(primarily, urinary incontinence) (placebo 1%, aripiprazole 
5%), excessive salivation (placebo 0%, aripiprazole 4%), and 
lightheadedness (placebo 1%, aripiprazole 4%).
Discontinuation due to AEs occurred in 10 patients on 
aripiprazole vs 7 patients on placebo in the De Deyn et al 
(2005) study, 14% on aripiprazole vs 9% patients on placebo 
in the Streim et al (2004) study. In the Mintzer et al (2007) 
study, discontinuation occurred in 8% on aripiprazole 2 mg/d, 
18% on aripiprazole 5 mg/d, 25% on aripiprazole 10 mg/d 
vs 13% patients on placebo. Thus the discontinuation due 
to AEs increased with increasing dose. The most common 
AE leading to discontinuation among the aripiprazole and 
placebo groups were asthenia and agitation, respectively. 
Discontinuations due to asthenia appeared to be dose-related, 
with the greatest number of patients experiencing asthenia 
in the aripiprazole 10 mg/day dose group (placebo 1%, 
aripiprazole 2 mg/day 1%, aripiprazole 5 mg/day 2%, and 
aripiprazole 10 mg/day 4%).
Discussion
The Clinical Antipsychotic Trials of Intervention Effective-
ness-Alzheimer’s Disease (CATIE-AD) study (Schneider 
et al 2006) evaluated the overall effectiveness of three of 
the most widely used antipsychotic medications compared 
with placebo among patients in non-nursing home settings, 
who were experiencing delusions, hallucinations, aggres-
sion, or agitation. The study followed the participants over 
9 months and also included the involvement of caregiv-
ers. In this 42-site, double-blind, placebo-controlled trial, 
421 outpatients suffering from AD and having psychosis, 
aggression, or agitation were randomly assigned to receive 
olanzapine (mean dose, 5.5 mg/d), quetiapine (mean dose, 
56.5 mg/d), risperidone (mean dose, 1.0 mg/d), or placebo. 
There were no signiﬁ  cant differences among treatments 
for the main outcome measures, ie, time to discontinua-
tion of treatment for any reason and number of patients 
with at least minimal improvement on the Clinical Global 
Impression of Change (CGIC) (Schneider et al 1997) 
scale at 12 weeks. The median time to discontinuation 
of treatment due to a lack of efﬁ  cacy favored olanzapine 
and risperidone over quetiapine and placebo. The time 
to discontinuation of treatment due to adverse events or 
intolerability favored placebo. This study showed that the 
adverse effects of atypical antipsychotics offset their ben-
eﬁ  ts in the treatment of psychosis, aggression, or agitation 
in patients with AD.
The ﬂ  exible dose studies of aripiprazole showed modest 
effect (Streim et al 2004; De Deyn et al 2005). In these 
two studies, which assessed the efﬁ  cacy of ﬂ  exible doses 
of aripiprazole up to 15 mg/d in patients with AD, the 
change from baseline NPI-NH Psychosis Subscale score 
was similar for the aripiprazole and placebo groups, with 
signiﬁ  cant improvements compared with placebo in sec-
ondary measures of psychosis (eg, BPRS score subscale 
and psychosis subscale) (De Deyn et al 2005) and other 
behavioral symptoms (eg, CMAI, CDDS,CGI-I, NPI-
NH scores) (Streim et al 2004) in patients suffering from 
psychosis associated with AD. The study assessing the 
efﬁ  cacy of ﬁ  xed doses of aripiprazole (Mintzer et al 2007) 
showed that aripiprazole 10 mg/d was efﬁ  cacious and safe 
for psychosis associated with AD, signiﬁ  cantly improving 
psychotic symptoms and agitation, and showed improve-
ment in both primary and secondary outcome measures in 
that patient population.
The safety and tolerability proﬁ  le of antipsychotic treat-
ment is of particular concern in elderly patients who are 
more susceptible to adverse effects such as EPS, delirium 
due to anticholinergic adverse events, and orthostatic 
hypotension. There is also a high prevalence of co-existing 
metabolic (eg, high cholesterol, diabetes mellitus) and 
cardiovascular illnesses (eg, hypertension, ischemic heart 
disease) in the elderly. In addition, AEs may be associated 
with falls and accidents resulting in fractures in the elderly. 
Hence the risk of such AEs should be considered while 
choosing a medication and making treatment decisions. It 
is therefore important to note that the incidence of EPS-
related AEs in these studies was low across all treatment 
groups. This concurs with the safety proﬁ  le of aripiprazole 
in patients with schizophrenia and bipolar disorder in adults 
and in elderly patients (Marder et al 2003; Madhusoodanan 
et al 2004; Sajatovic et al 2008). However, not all studies 
with atypical antipsychotics in patients with AD have shown 
EPS-related adverse events similar to placebo (Street et al 
2000). High levels of somnolence may also be associated 
with falls in the elderly. In the two studies assessing the 
ﬂ  exible doses of aripiprazole, occurrence of somnolence 
showed a 5% difference between the aripiprazole and 
placebo groups. In the study assessing fixed doses of 
aripiprazole, the incidence of somnolence with aripiprazole 
was low (7% at the 10 mg/d dose) and did not increase 
with dose. Higher somnolence rates have been observed 
in previous studies with other atypical antipsychotics. for Clinical Interventions in Aging 2008:3(3) 499
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example, 36.5% with risperidone (Brodaty et al 2003) and 
35.8% with olanzapine (Street et al 2000). There was no 
signiﬁ  cant difference between placebo and aripiprazole in 
all the three studies for weight change, in contrast to stud-
ies with other atypical antipsychotics where signiﬁ  cantly 
higher weight gain was observed with both olanzapine (De 
Deyn et al 2004) and risperidone (Brodaty et al 2003) vs 
placebo in patients with AD.
Recently, CVAEs have emerged as a signiﬁ  cant issue 
with the use of atypical antipsychotics in elderly individu-
als (Wooltorton 2002, 2004). This led the FDA to issue a 
warning. However, some retrospective cohort studies have 
suggested that conventional and atypical antipsychotics do 
not differ signiﬁ  cantly in their risk of CVAEs (Herrmann et al 
2004; Finkel et al 2005) or mortality (Wang et al 2005) in 
older adults. CVAEs were reported for 7 aripiprazole-treated 
patients during the Mintzer et al (2007) ﬁ  xed dose study (1 in 
the 2 mg/d dose group, 2 in the 5 mg/d dose group, and 4 in 
the 10 mg/d dose group), compared with no patients in the 
placebo group. The effect was statistically dose-dependent 
(p = 0.03, Cochran–Mantel–Haenszel [CMH] row means 
score test). All CVAEs reported with aripiprazole occurred 
in subjects with a prior history of CVA, stroke, or related risk 
factors. It is also important to note that the FDA has issued 
a black box warning for increased mortality risk in elderly 
patients with dementia, treated with atypical antipsychotics 
(US FDA 2003). Analyses of 17 placebo-controlled trials 
(modal duration of 10 weeks) in these patients revealed a risk 
of death in the drug-treated patients of 1.6 to 1.7 times to that 
seen in placebo-treated patients. Over the course of a typical 
10-week controlled trial, the rate of death in drug-treated 
patients was about 4.5%, compared with a rate of about 
2.6% in the placebo group. Although the causes of death 
were varied, most of the deaths appeared to be the result of 
either cardiovascular causes (eg, heart failure, sudden death) 
or infections (eg, pneumonia). Aripiprazole should be used 
with caution in patients with known cardiovascular disease, 
cerebrovascular disease, or conditions that would predispose 
patients to hypotension. The risks and beneﬁ  ts of arpipirazole 
in the treatment of psychosis of AD should be considered 
by the clinicians and discussed with the patients/caregivers 
(Schneider et al 2005).
A thorough evaluation of the medical and psychiatric 
status along with a comprehensive treatment approach 
including environmental manipulation are required prior 
to considering use of atypical antipsychotic in patients 
with psychosis associated with AD. The efﬁ  cacy results in 
the study by Mintzer et al (2007) show that aripiprazole 
10 mg/d is an effective dose for these patients, although 
some patients achieved signiﬁ  cant beneﬁ  t with aripiprazole 
5 mg/d. The dose–effectiveness relationship is further sup-
ported by the rate of discontinuation due to lack of efﬁ  cacy, 
which was greatest in the 2 mg/d dose group. However, when 
selecting an appropriate dose, the discontinuation rate due to 
dose-related adverse events should also be considered. The 
rates of discontinuation due to adverse events for the 5 and 
10 mg/d doses (18% and 25%, respectively) were higher 
than those reported in the ﬂ  exible-dose aripiprazole studies 
in noninstitutionalized patients (9.4%) (De Deyn et al 2005) 
and in institutionalized patients (14%) (Streim et al 2004). In 
both of the ﬂ  exible-dose studies, patients were started with 
2 mg/d and titrated gradually to higher aripiprazole doses. 
This suggests that slow titration from a low initial dose may 
improve the tolerability and prove to be the most clinically 
appropriate strategy for starting aripiprazole treatment in this 
elderly patient population.
Conclusion
The control of psychotic symptoms is important for improv-
ing outcome in elderly patients with AD. Furthermore, 
treatment of the psychotic symptoms improves patient 
quality of life, decreases caregiver burden, decreases the 
need for institutionalization, and reduces overall healthcare 
costs. There are no psychotropic medications approved by 
the FDA for the treatment of psychosis of AD. The limited 
evidence available for atypical antipsychotics suggests that 
they offer modest beneﬁ  ts over placebo for treating psycho-
sis. The studies evaluating aripiprazole suggest that it may 
also be beneﬁ  cial in treatment of psychosis for patients with 
AD. However, the beneﬁ  ts of relieving psychosis need to 
be balanced against the risk of neurologic, metabolic, and 
cardiovascular AEs in each individual patient. The safety 
and tolerability proﬁ  le seen with aripiprazole suggests a low 
potential for negative impact on overall patient health and 
makes aripiprazole a reasonable treatment option. However, 
in the absence of head-to-head comparison studies between 
aripiprazole and other atypical antipsychotics, it is difﬁ  cult 
to conclude whether there is any added value of the uses of 
aripiprazole. Further studies comparing the efﬁ  cacy and toler-
ability of aripiprazole versus other atypical antipsychotics in 
psychosis of AD are needed to guide treatment choice among 
the atypical antipsychotics agents.
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